Eurofins Scientific, a world leader in bioanalytical tests announces the acquisition of Beacon Discovery, a contractual research (ORC) and drug discovery organization specializing in research on G protein-coupled receptors (GPCRs). Beacon Discovery integrates Eurofins Discovery, a leading CRO with the broadest portfolio of validated in vitro pharmacology, ADMET , and chemistry services for integrated drug discovery solutions. The transaction should be finalized in the coming weeks, subject to the satisfaction of customary closing conditions.

Eurofins acquired Beacon Discovery for its innovative approach, years of experience in drug discovery and development, as well as for its deep expertise in GPCR research, complemented by its unrivaled library of compounds. The acquisition of Beacon Discovery consolidates Eurofins' strategy, which consists of becoming the essential partner of the pharmaceutical industry, by bringing experience in drug discovery, knowledge and a proven track record in the discovery and development of new therapeutic agents. Beacon Discovery significantly enhances the capabilities and innovative methods of Eurofins Discovery to support and accelerate drug research and development, and to seize opportunities for

Dr Sunny Al-Shamma, CEO of Beacon Discovery, said: "Beacon Discovery is delighted to join Eurofins. Our arrival in the Eurofins Discovery organization strengthens our ability to continue our drug discovery efforts and provides integrated services in this area. , coupled with the additional capacities provided by Eurofins Discovery ".

Dr Gilles Martin, CEO of Eurofins, said: "Beacon Discovery strengthens expertise in GPCR targets, drug discovery and development experience in order to diversify our integrated service offering. This transaction once again demonstrates our commitment of Eurofins to provide the most comprehensive possible portfolio of laboratory services in the field of pharmacological discovery, which is currently experiencing a strong trend towards outsourcing.